Patents Examined by Zohreh Fay
  • Patent number: 10244760
    Abstract: The present invention relates to an ophthalmic solution comprising 0.00001 to 10.0 weight percent of a simple saccharide, at least 0.00001 weight percent of a preservative, and not more than about 0.2 percent by weight chloride. The simple saccharide is chosen from the group consisting of: inositol; mannitol; sorbitol; sucrose; dextrose; glycerin; propylene glycol; ribose; triose; tetrose; erythrose; threose; pentose; arabinose; ribulose; xylose; xylulose; lyxose; hexose; allose; altrose; fructose; galactose; glucose; gulose; idose; mannose; sorbose; talose; tagatose; adlose; ketose; heptose; sedoheptulose; monosaccharides; disaccharides; sugar alcohols; xylitol; and polyol.
    Type: Grant
    Filed: January 26, 2018
    Date of Patent: April 2, 2019
    Assignee: FXS VENTURES, LLC
    Inventor: Francis X. Smith
  • Patent number: 10238635
    Abstract: There is provided a composition for treating a neuroinflammatory disease comprising a N-carbamoylated urethane compound which has an effect of inhibiting the activity of microglia or astrocytes and the production of nitric oxide (NO) and TNF-?, and suppressing the expression of IL-1? And iNOS genes. There is also provide a method for treating a neuroinflammatory disease, the method comprising the step of administering a N-carbamoylated urethane compound. Due to its above mentioned effects, the N-carbamoylated urethane compound according to the present invention can be useful for the treatment of neuroinflammatory diseases.
    Type: Grant
    Filed: April 24, 2017
    Date of Patent: March 26, 2019
    Assignee: Kyungpook National University Industry-Academic Cooperation Foundation
    Inventors: Kyoungho Suk, Gyun Jee Song, Youngpyo Nam, Myungjin Jo
  • Patent number: 10238616
    Abstract: An immunomodulator useful for modulating immune function and maintaining intravital homeostasis is provided. The immunomodulator comprises S-1-propenycysteine or a salt thereof as an active ingredient.
    Type: Grant
    Filed: December 4, 2015
    Date of Patent: March 26, 2019
    Inventors: Junichiro Suzuki, Yukihiro Kodera, Kenji Itoh, Toshiaki Matsutomo
  • Patent number: 10227308
    Abstract: The present invention relates to a compound of formula (I) wherein R1 is defined as in the description and in the claims. The compound of formula (I) can be used as radiolabeled ligand.
    Type: Grant
    Filed: February 27, 2017
    Date of Patent: March 12, 2019
    Inventors: Simon M. Ametamey, Juergen Fingerle, Luca Gobbi, Uwe Grether, Ahmed Haider, Thomas Hartung, Linjing Mu, Leo Nicholls, Mark Rogers-Evans, Christoph Ullmer
  • Patent number: 10226420
    Abstract: A method comprising administering an effective amount of a topical dipyridamole to a subject in need thereof due to conjunctivitis.
    Type: Grant
    Filed: November 30, 2017
    Date of Patent: March 12, 2019
    Inventor: Moshe Rogosnitzky
  • Patent number: 10220021
    Abstract: Uses of melanin and its derivatives, analogs, and precursors for the treatment and prevention of ocular diseases, disorders, and conditions, are described. Melanin, or a derivative, analog, or precursor thereof, such as synthetic melanin or natural melanin, is applied to the eye by topical application or injection. Examples of ocular diseases, disorders, and conditions that can be treated or prevented by the methods described herein include hyperemia, leukoplakia, corneal angiogenesis, and corneal keratoconus.
    Type: Grant
    Filed: September 8, 2015
    Date of Patent: March 5, 2019
    Inventor: Arturo Solis Herrera
  • Patent number: 10213392
    Abstract: The invention relates to the manufacturing and use of pharmaceutical compositions of medicines (ophthalmic preparations) comprising a mitochondria-addressed antioxidant and a set of auxiliary substances providing effective treatment for ophthalmological diseases in humans and animals.
    Type: Grant
    Filed: July 12, 2017
    Date of Patent: February 26, 2019
    Assignee: MITOTECH SA
    Inventor: Maxim V. Skulachev
  • Patent number: 10213431
    Abstract: The present invention is directed to preservative-free solutions of brimonidine and timolol for lowering intra-ocular pressure and treatment of glaucoma.
    Type: Grant
    Filed: July 28, 2011
    Date of Patent: February 26, 2019
    Assignee: Allergan, Inc.
    Inventors: Sukhon Likitlersuang, Ajay Parashar, Chetan P. Pujara, William F. Kelly
  • Patent number: 10214531
    Abstract: The invention provides novel substituted amino triazoles of Formula (I), or a pharmaceutically acceptable salt, hydrate or solvate thereof, as well as pharmaceutical compositions comprising the same. The compounds of the invention are inhibitors of acidic mammalian chitinase (AMCase) and are useful, in a non-limiting embodiment, for treating asthma. The invention further provides methods of using compounds and/or compositions of the invention to treat asthma and/or to monitor asthma treatment.
    Type: Grant
    Filed: December 19, 2014
    Date of Patent: February 26, 2019
    Assignee: Institute for Drug Discovery, LLC
    Inventors: Michael L. Corman, William M. Hungerford, Adam Golebiowski, Raymond P. Beckett, Marzena Mazur, Sylwia Olejniczak, Jacek Olczak
  • Patent number: 10201534
    Abstract: Provided herein is an ophthalmic composition. In some embodiments, the ophthalmic composition includes a low concentration of an ophthalmic agent for treatment of an ophthalmic disorder or condition; and an ophthalmically acceptable carrier, wherein the ophthalmic agent is distributed with substantial uniformity throughout the ophthalmically acceptable carrier. Further disclosed herein include an ophthalmic composition including a low concentration of an ophthalmic agent and deuterated water. Also disclosed herein are methods of arresting or preventing myopia development by administering to an eye of an individual in need thereof an effective amount of an ophthalmic composition as described herein.
    Type: Grant
    Filed: February 13, 2018
    Date of Patent: February 12, 2019
    Assignee: SYDNEXIS, INC.
    Inventors: Gregory I. Ostrow, Kenneth J. Widder, David S. Baker
  • Patent number: 10201548
    Abstract: A method of treating blepharitis includes administering to the affected eye of a subject an effective amount of an active ingredient in an ophthalmically acceptable vehicle for a sufficient period of time to treat blepharitis. The active ingredient consists essentially of a glucocorticoid in an ophthalmically acceptable vehicle that includes an aqueous polymer suspension that when mixed with tear fluid provides a sustained release of said active ingredient. The aqueous polymer suspension includes a carboxyl-containing polymer having less than about 5% by weight cross-linking agent and has a viscosity in a range from about 1,000 to about 30,000 centipoises. A kit includes: (a) a composition comprising about 0.1% by weight dexamethasone in this ophthalmically acceptable vehicle and (b) instructions for using the composition of (a) for the treatment of blepharitis.
    Type: Grant
    Filed: March 6, 2009
    Date of Patent: February 12, 2019
    Inventors: Lyle Bowman, Kamran Hosseini
  • Patent number: 10188752
    Abstract: A ferumoxytol-based dual-modality imaging probe for long-term stem cell tracking through MRI and early diagnosis of cell apoptosis through simultaneous fluorescence imaging is provided. Specifically, a ferumoxytol-based dual-modality imaging probe is provided with enhanced T2* relaxivity for tracking stem cells through magnetic resonance imaging and detecting apoptotic stem cells through fluorescence imaging.
    Type: Grant
    Filed: August 4, 2017
    Date of Patent: January 29, 2019
    Assignee: The Board of Trustees of the Leland Stanford Junior University
    Inventors: Kai Li, Heike E. Daldrup-Link, Hossein Nejadnik
  • Patent number: 10183014
    Abstract: The present application relates to topical formulations comprising Compound-I or its free base, and a second active agent selected from nicotinic acid, nicotinamide, and vitamin K, and a combination thereof, for treating ocular neovascularization. The present application also relates to pharmaceutical compositions comprising particles of Compound-I or its free base, and suspension formulations comprising the particle compositions of Compound-I or its free base.
    Type: Grant
    Filed: September 28, 2017
    Date of Patent: January 22, 2019
    Inventors: David P. Bingaman, Paul G. Chaney, Martin B. Wax
  • Patent number: 10182566
    Abstract: Provided are a sustained release pheromone preparation capable of maintaining a high amount of pheromone release throughout a control period of vine mealybug (VMB) having lavandulyl senecioate (LVSN) as a pheromone substance; and a control method with the preparation. More specifically, provided are a sustained release pheromone preparation comprising a first pheromone substance, and a first container having the first pheromone substance sealed therein and comprising a first polymer membrane made of an ethylene vinyl acetate copolymer containing vinyl acetate units of from 0.5 to 10% by weight, wherein the first pheromone substance is lavandulyl senecioate, which is a pheromone substance of vine mealybug, and the lavandulyl senecioate can be released into the air through the first polymer membrane for 150 days or more; and others.
    Type: Grant
    Filed: February 28, 2017
    Date of Patent: January 22, 2019
    Assignee: Shin-Etsu Chemical Co., Ltd.
    Inventors: Tatsuya Hojo, Takeshi Kinsho, Erina Ohno, Miyoshi Yamashita
  • Patent number: 10179138
    Abstract: The present invention relates to a pharmaceutical composition comprising (a) 7?-hydroxycholesterol, (b) a water soluble organic solvent, preferably propylene glycol and/or DMSO, and (c) a solubilizing agent, preferably PEG hydrated castor oil, and to a method for preparing the same. This composition is suitable for preparing an intravenously administered preparation and comprises the pharmaceutically active substance ?-hydroxycholesterol, which is poorly soluble in water.
    Type: Grant
    Filed: January 12, 2017
    Date of Patent: January 15, 2019
    Assignee: IMMUNOPHARM AG
    Inventors: Werner Bieberschulte, Christine Grimm, Rohan Charles Fernando
  • Patent number: 10159669
    Abstract: Disclosed are pharmaceutical compositions comprising mdivi-1 and nutlin-3, individually and in combination, for topical or intravitreal ophthalmic delivery and a method of treatment comprising administering said composition when indicated for glaucoma, optic neuropathies including Leber Hereditary Optic Neuropathy, arteritic or non-arteritic Ischemic Optic Neuropathy, and retinal artery and vein occlusions.
    Type: Grant
    Filed: March 2, 2010
    Date of Patent: December 25, 2018
    Inventor: Ian H. Chan
  • Patent number: 10138384
    Abstract: The present invention relates to a lens care solution having 0.001 to about 5 weight percent of a low molecular weight amine of the general formula: where R1, R2, R3 and R4 are —H or low molecular weight radicals, and R5 is a low molecular weight radical, or salt thereof; an effective amount of a tonicity agent; and the balance water.
    Type: Grant
    Filed: September 7, 2017
    Date of Patent: November 27, 2018
    Assignee: FXS Ventures, LLC
    Inventor: Francis X. Smith
  • Patent number: 10137084
    Abstract: Bethanechol is administered topically, for the treatment of xerostomia.
    Type: Grant
    Filed: April 6, 2016
    Date of Patent: November 27, 2018
    Assignee: Acacia Pharma Limited
    Inventors: Nicola Cooper, Julian Clive Gilbert, Robert William Gristwood, Michael Grant Wyllie
  • Patent number: 10123896
    Abstract: Methods and apparatus for inducing weight loss using blood flow control are described herein. The apparatus and methods operate by controlling blood flow to the stomach and/or small bowel.
    Type: Grant
    Filed: March 5, 2015
    Date of Patent: November 13, 2018
    Assignee: Mayo Foundation for Medical Education and Research
    Inventors: Gianrico Farrugia, Paul A. Friedman, Elizabeth Rajan, Charles J. Bruce, Samuel J. Asirvatham, Michael J. Levy, Louis-Michel Wong Kee Song, Juliane Bingener-Casey, Navtej S. Buttar
  • Patent number: 10117967
    Abstract: The embodiments herein disclose a method of fabricating composite scaffolds for skin tissue regeneration. The methacrylated hyaluronic acid (HAMA) and methacrylated gelatin (GelMA) are synthesized. The poly (glycerol sebacate)-poly(?-caprolactone) (PGS-PCL) microfibrous scaffolds are synthesized. The hydrogel is synthesized. The composite scaffold comprising hydrogel and poly (glycerol sebacate)-poly(?-caprolactone) (PGS-PCL) microfibrous scaffolds is fabricated. A plurality of physico-chemical characteristics of the composite scaffold comprising hydrogel and poly (glycerol sebacate)-poly(?-caprolactone) (PGS-PCL) microfibrous scaffolds are analysed. The physico-chemical characteristics comprises mechanical properties, swelling ratio and enzymatic degradation and scanning electron microscope imaging. The fibroblast cells are encapsulated within the composite scaffold comprising hydrogel and poly (glycerol sebacate)-poly(?-caprolactone) (PGS-PCL) microfibrous scaffolds and hydrogels.
    Type: Grant
    Filed: October 11, 2017
    Date of Patent: November 6, 2018
    Inventors: Maryam Eslami, Parvaneh Reshteh Ahmadi, Alireza Eslami